The ENPP2 antibody targets the enzyme ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), also known as autotaxin. ENPP2 is a secreted glycoprotein that plays a critical role in lysophosphatidic acid (LPA) production by hydrolyzing lysophosphatidylcholine (LPC) to generate LPA, a bioactive lipid mediator involved in diverse physiological and pathological processes. ENPP2 is implicated in cell proliferation, migration, and survival, and its dysregulation has been linked to cancer progression, fibrosis, inflammation, and neurological disorders.
ENPP2 antibodies are essential tools for studying the enzyme’s expression, localization, and function in vitro and in vivo. They are widely used in applications such as Western blotting, immunohistochemistry (IHC), and ELISA to quantify ENPP2 levels in tissues or biological fluids, aiding research into disease mechanisms. Some antibodies specifically recognize distinct structural domains of ENPP2. such as its catalytic site or hydrophobic channel, enabling functional studies or inhibition assays.
Therapeutic interest in ENPP2 has grown due to its role in promoting tumor metastasis and angiogenesis. Neutralizing antibodies against ENPP2 are being explored as potential therapeutics to block LPA signaling in cancers or fibrotic diseases. Commercially available ENPP2 antibodies vary in clonality (monoclonal/polyclonal), species reactivity, and validation standards, necessitating careful selection based on experimental needs.